HDAC9 and neoplasm: While specific, large-scale clinical trials dedicated solely to HDAC inhibitors for WT may be limited, research indicates that HDAC inhibitors show promise as a therapeutic approach for WT, particularly in combination with other targeted therapies like EZH2 inhibitors [41], and pre-clinical studies have demonstrated their efficacy in inhibiting tumor growth and inducing apoptosis in WT cells and models [42].